Cochrane · systematic review · CD009226
Rituximab for thyroid‐associated ophthalmopathy
Kang, S, Hamed Azzam, S, Minakaran, N, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 12 · 85.7%Low 2 · 14.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings table ‐ Rituximab compared to intravenous methylprednisolone for thyroid‐associated ophthalmopathy
Population: thyroid‐associated ophthalmopathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
CAS improvement (decrease) by 2 or more points Summary of findings table ‐ Rituximab vs intravenous methylprednisolone | RR 1.32 [0.98, 1.78] | 1 study · 31 participants | Low Downgraded: risk of bias, imprecision |
NOSPECS improvement (decrease) by 2 or more classes Summary of findings table ‐ Rituximab vs intravenous methylprednisolone | RR 1.07 [0.25, 4.49] | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision |
Proptosis improvement (decrease) by 2 mm or more Summary of findings table ‐ Rituximab vs intravenous methylprednisolone | RR 0.35 [0.02, 8.08] | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision |
Palpebral aperture improvement (decrease) by 3 mm or more Summary of findings table ‐ Rituximab vs intravenous methylprednisolone | RR 5.31 [0.28, 102.38] | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision |
Motility improvement (increase) by 1 class or more Summary of findings table ‐ Rituximab vs intravenous methylprednisolone | RR 1.07 [0.25, 4.49] | 1 study · 31 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life improvement by at least 6 points Summary of findings table ‐ Rituximab vs intravenous methylprednisolone | no estimate extracted | 1 study · 27 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events Summary of findings table ‐ Rituximab vs intravenous methylprednisolone | RR 1.39 [0.9, 2.13] | 1 study · 31 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings table ‐ Rituximab compared to placebo for thyroid‐associated ophthalmopathy
Population: thyroid‐associated ophthalmopathy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
CAS improvement (decrease) by 2 or more points Summary of findings table ‐ Rituximab vs placebo | RR 1.23 [0.34, 4.4] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
NOSPECS improvement (decrease) by 2 classes or more Summary of findings table ‐ Rituximab vs placebo | RR 0.92 [0.15, 5.56] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Proptosis improvement (decrease) by 2 mm or more Summary of findings table ‐ Rituximab vs placebo | RR 0.46 [0.1, 2.08] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Palpebral aperture change Summary of findings table ‐ Rituximab vs placebo | no estimate extracted | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Motility Summary of findings table ‐ Rituximab vs placebo | no estimate extracted | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Quality of Life Summary of findings table ‐ Rituximab vs placebo | no estimate extracted | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects Summary of findings table ‐ Rituximab vs placebo | RR 2.46 [0.84, 7.18] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |